MedTrace Logo

HP 129Xe MRI for Evaluation of CLAD in Lung Transplant Recipients

NCT05550662 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-09-04

No results posted yet for this study

Summary

To evaluate the feasibility of hyperpolarized 129Xe MRI in lung transplant recipients and assess structural and functional pulmonary changes using hyperpolarized 129Xe MRI

Conditions

  • Lung Transplant Rejection

Interventions

DRUG

129Xenon

There is no study medication evaluated. As part of the MRI, participants will inhale hyperpolarized 129Xe gas at a dose of up to 1/6th of total lung capacity (TLC) (lung volume), mixed with nitrogen to a total volume of 1.5 L. The polarized 129Xe will be inhaled in a single breath-hold. This is intended to fill the lungs gas, allowing for lung MRI.

Sponsors & Collaborators

  • University Health Network, Toronto

    collaborator OTHER

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • Giles Santyr, PhD · The Hospital for Sick Children

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-07
Primary Completion
2024-08-02
Completion
2024-08-02

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05550662 on ClinicalTrials.gov